Ontology highlight
ABSTRACT:
SUBMITTER: Pape UF
PROVIDER: S-EPMC7692271 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
Pape Ulrich-Frank UF Kasper Stefan S Meiler Johannes J Sinn Marianne M Vogel Arndt A Müller Lothar L Burkhard Oswald O Caca Karel K Heeg Steffen S Büchner-Steudel Petra P Rodriguez-Laval Victor V Kühl Anja A AA Arsenic Ruza R Jansen Holger H Treasure Peter P Utku Nalân N
Cancers 20201027 11
CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours. In a Phase II trial, 27 patients with advanced biliary tract cancers (BTC) were randomised 1:1 to CAP7.1 plus best supportive care (BSC), or BSC alone, with crossover to CAP7.1 upon disease progression. The primary objective was disease control rate (DCR) following 28-day cycles of CAP7.1 (200/150 mg/m<sup>2</sup>; iv), or BSC ...[more]